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Abstract
Background: Epidural analgesia with bupivacain, epinephrine and fentanyl provides excellent pain control after
lumbar fusion surgery, but pruritus and motor block are frequent side effects. Theoretically epidural ropivacain
combined with oral oxycodone could decrease the incidence of these side effects. The two regimens were
compared in a prospective randomized trial.
Patients and methods: 150 patients (87 women) treated with posterior instrumented lumbar fusion were
included. The mean age was 51 +/- 11 years. 76 were randomized to bupivacain, epinephrine and fentanyl (group
B) and 74 to ropivacain and oxycodone (group R). Pruritus, motor block and pain were measured 6 hours after
surgery, thereafter 6 times per day for 5 days. Any pain breakthrough episode was registered whenever it occurred.
Results: The epidural treatment could be performed in 143 patients (72 in group B and 71 in group R). Disturbing
pruritus occurred in 53 patients in group B compared to 12 in group R (p < 0.0001). Motor blockade was most
frequent on day 1, occurring in 45% of the patients with no difference between the groups. Both regimes gave
good pain control with average VAS under 40, but the pain relief was statistically better in group B. The number of
pain breakthrough episodes did not differ between the groups.
Conclusions: Pruritus could be reduced with a combination of epidural ropivacain and oral oxycodone, at the
price of a slightly higher pain level. Ropivacaine was not found to be superior to bupivacaine with regard to motor
blocks.
Introduction
The postoperative pain level after posterior instrumen-
ted lumbar spine fusion surgery is generally high, thus
an efficient pain control regime is required. Continuous
epidural analgesia (CEA) with bupivacain, epinephrine
and fentanyl for three days followed by oral analgesics is
an effective postoperative treatment option [1,2]. This
regime has been used successfully for many years, but
pruritus and motor blocks are frequently encountered
side effects. Pruritus is considered to be caused by
epidural administration of opiates [3,4]. Unbearable
pruritus leads to an early termination of CEA in multi-
ple cases exposing the patients to an increased risk of a
pain breakthrough before the alternative pain regime
has reached its full effect. Furthermore, any paresis in
the postoperative period after spine surgery has to be
distinguished from a serious complication to the opera-
tive procedure itself. Thus, in case of a motor block the
CEA has to be stopped and the patient monitored clo-
sely until motor function returns, which may lead to
temporary insufficient pain control. Pain breakthrough
episodes may also occur in the transition to oral medi-
cation at the end of CEA treatment before the oral
treatment has reached full effectiveness.
CEA with ropivacain combined with oral slow release
oxycodone has theoretical advantages to CEA with
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opioids may decrease the incidence of pruritus. Addi-
tionally, the motor block effect of ropivacain is consid-
ered to be lower than that for bupivacain. Furthermore
the risk for pain breakthrough episodes at time of epi-
dural removal is lower if the patient already is treated
with an oral slow release opiate when the CEA effect
wears off.
In an unpublished small non-randomized pilot study
comparing CEA with bupivacain, epinephrine and fenta-
nyl to CEA with ropivacain combined with intravenous
opiates, we saw a decrease in pruritus and motor blocks
and fewer problems with pain breakthrough episodes
during treatment and at discontinuation when ropiva-
cain was used. Therefore a randomized trial would be of
value to investigate whether the postoperative period
could be significantly improved for lumbar spine fusion
patients, using a different epidural analgesia protocol.
The aim of this study was to compare the effectiveness
of two different pain control regimes after posterior
instrumented lumbar fusion surgery for degenerative
conditions in a randomized trial.
Patients and methods
The study was approved by the Regional Ethics Com-
mittee in Stockholm (2007-001417-41), and written
informed consent was obtained from all subjects.
Included were patients between 18 and 70 years of
age, being treated with one to four level posterior
instrumented lumbar spine fusion for degenerative con-
ditions. Exclusion criteria were: use morphine analgesics
before surgery, known allergy for any of the used drugs,
any known contraindication to CEA, psychiatric disease
or language problems, which would have led to great
difficulties understanding the instructions or communi-
cating the results.
The series consisted of 150 patients (87 women and
63 men), with a mean age of 51 ± 11 years. Seventy-six
were randomized to group B and 74 to group R after
having received written information and given consent.
The baseline demographics, indications for surgery, and
preformed procedures are listed in Table 1. There were
no differences between the groups with regard to base-
line data.
Treatment protocol
One hour before the operation the premedication was
given. The patients were operated under general anaes-
thesia. In both treatment groups an 18 G epidural cathe-
ter was inserted openly with the tip at the lower thoracic
region towards the end of the operation. The CEA was
continued for three days. The patients in both groups
adjuvant paracetamol 1 g × 4 was included in the treat-
ment. For the detailed CEA protocols see Table 2.
Sample size calculation
Pruritus was the primary variable of interest. In our
pilot study pruritus was present in 40% of patients
receiving CEA with bupivacain, epinephrine and fenta-
nyl. A decrease to 10% would be considered a clinically
successful reduction. With 5% significance level and
80% power 49 patients would have to be included in
each group. Corresponding figures for motor blockade
is 35 patients and for pain breakthrough episodes 67
patients. As CEA presumably must be terminated in
several cases because of a lack of effect we chose to
include 75 patients in each group to cover for these and
other losses.
Randomization
Randomization was done using numbered closed envel-
ops which were filled in accordance to a computer gen-
erated randomization list. The patients were given
envelopes consecutively as they were entered into the
study. The envelope was opened and the patient
informed when the premedication was given just before
the patient was brought to the OR.
Data collection
Pruritus was measured according to an arbitrary scale: 0
- no pruritus; 1 - mild pruritus not requiring any medi-
cal treatment; 2 - moderate pruritus requiring medical
treatment; 3 - severe pruritus leading to discontinuation
of the treatment. The highest score for each day was
used for the further analysis.
Motor blockade was registered according to Bromage
[5]: 0 - Free movements of legs and feet; 1 - Just able to
Table 1 Baseline data of the two treatment groups
Group B Group R
Women/men 43/33 44/30
Age ± SD 51.6 ±
10.2
50.2 ±
10.6
Diagnosis Spondylolysis/-olisthesis 17 13
Disk herniation 2 4
Spinal stenosis 26 18
Degenerative disc disease 28 34
Non-union of previous fusion 3 5
Treatment Decompression and posterior
fusion
27 24
Posterior fusion without
decompression
16 21
Posterior lumbar interbody fusion 33 29
Levels
fused
15 3 4 3
21 9 2 7
34 2
40 2
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knees, free movements of feet; 3 - Unable to move legs
or feet. The highest score on the worst side for each day
was used for the further analysis.
Pain was measured with a visual analogue scale (VAS)
from 0 (no pain) to 100 (worst possible pain) [6]. A
mean VAS score for each day was calculated and used
for the further analysis.
All patients were evaluated on a set time schedule
every fourth hour for five days. However, if the patient
was sound asleep during the night the analgesia effect
was considered satisfactory and he/she was not awa-
kened for data acquisition. In addition an extra registra-
tion was done at six hours after surgery.
A pain breakthrough episode was defined as VAS ≥70
and the number of these events was registered for each
patient, as was the number of extra doses of opiates given.
Statistical Analysis
The primary variable pruritus was dichotomised as
a b s e n t ,i . e .s c o r e0o r1 ,o rp r e s e n t ,i . e .s c o r e2o r3 ,
registered at any time during the study period. The two
study groups were then compared using Fisher’se x a c t
test. Presence of pruritus was also compared between
the treatment groups with repeated measurement
ANOVA, as was presence of motor blockade and pain
scores. The number of pain breakthrough episodes and
extra doses of opiates were compared with non-para-
metric tests. P < 0.05 was considered significant.
Results
One-hundred-and-fifty patients were included in the
study; 76 were randomized to group B and 74 to group
R. The CEA treatment could not be initiated in 7
patients: one patient in group B developed a stroke and
died shortly after the operation; a further investigation
ruled out any association to the applied pain treatment.
The epidural catheter was not functional in 6 cases
most likely due to occlusion or dislocation.
Clinically relevant pruritus (grade 2 or 3 according to
our scale) was present in 74% in group B compared to
17% in group R, P < 0.0001 (Table 3). In group B the
elevated pruritus level was present already at 6 hours
after the operation, reached a maximum at day 1 and 2,
and remained elevated until the CEA was removed at
day 4 whereas the pruritus level in group R was fairly
constant during the entire study period (Figure 1).
Motor blockade varied over time reaching a maximum
during day 1 when 45% of the patients were affected.
However, the motor blockade was in the majority of
cases of the mildest form, and more pronounced pro-
blems were seldom seen. There was no difference
between the treatment groups (Figure 2 and Table 4).
Table 2 CEA protocols for group B (standard protocol) and group R (experimental protocol)
Group B Group R
premedication 1 g oral paracetamol. 20 mg oral slow release oxycodone and
1 g oral paracetamol.
CEA/analgesia
solution
Bupivacain 1 mg/ml, Epinephrine 2 μg/ml, and Fentanyl 2 μg/ml. Ropivacain 2 mg/ml, combined with 20 mg oral slow
release oxycodone with 12 hours interval.
Test dose before
wound closure
2 ml bupivacain 5 mg/ml with epinephrine 5 μg/ml. 2 ml ropivacain 5 mg/ml with epinephrine 5 μg/ml.
If no adverse reaction was seen during a few minutes another dose of 5 to 7 ml was given.
CEA dosage Initial dose 4 to 6 ml per hour combined with patient administered bolus doses of 2 ml with a maximum of 3 boluses per hour.
The slow release oxycodone was continued twice a day.
Duration of CEA 72 hours, transition to oral slow release oxycodone 20 mg twice a
day.
72 hours, while the oral slow release oxycodone treatment
was continued.
Pain
breakthrough
rescue treatment
Boluses of 2-6 ml were given and/or the epidural catheter was manipulated if indicated.
If the initial treatment would fail CEA was exchanged to
bupivacain-only combined with patient controlled intravenous
opiate, morphine or ketobemidone.
If this initial treatment would fail extra oral oxycodone or
intravenous opiates, morphine or ketobemidone, may be
added. If also this would fail patient controlled intravenous
opiates was applied.
Table 3 Summary of daily pruritus level counts
Group B Group R
d a y 1234512345
Pruritus
0 12 10 29 50 62 59 46 61 61 66
1 11 17 24 14 3 6 12 5 5 2
2 43 39 13 2 1 3 10 2 2 0
3 0000000000
The number of patients with clinical relevant pruritus, i.e. defined as grade 2
or 3 in our scale, in the two treatment groups differed significantly in favour
of group R, P < 0.0001.
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groups with the mean VAS-value regularly below 40.
There was, however, a statistically significant difference
between the groups in favour of group B throughout the
CEA treatment period of 10-14 VAS units. There was
also a statistically significant increase in VAS-value in
group B during the day of CEA removal (Figure 3).
There was no difference between the treatment groups
with respect to pain breakthrough episodes: 83 of the
patients experienced 303 pain breakthrough episodes
during the entire study period, 40 patients and 126 epi-
sodes in group B compared to 43 patients and 177 epi-
sodes in group R (n.s.). Pain breakthrough episodes
during day 4, i.e. the day of CEA removal, amounted to
25 patients in group B compared to 17 patients in
group R (n.s.). 76% of the patients in both treatment
groups received extra doses of opiates during day 4
without any significant difference between the groups
(Table 5).
In group B 5/72 patients and in group R 3/71 had to
discontinue the CEA treatment prematurely (n.s.). In
group B: 3 patients due to severe pruritus and 2 patients
due to unsatisfactory pain control. In group R: 2
patients due to motor blockade and 1 patient due to
unsatisfactory pain control. In addition 3 patients, all in
group R, were discharged home already on day 4
because they were fully mobilized and no longer in need
of hospital care. No data were collected on day five for
these patients. The parameters for all these patients
were included in the group analysis for the time they
were available for the study.
There were no gender differences.
Discussion
In the presented randomized trial dramatically lower
pruritus levels were found if epidural use of opioids was
avoided. This confirms the findings in the recently pub-
lished randomized trial of Prasartritha et al [7] who
found increased pruritus if epidural fentanyl was used
after lumbar spine surgery. Postoperative pain levels as
measured with VAS were lower in our study if opoiods
were administered epidurally. Thus the investigated
experimental CEA protocol using ropivacain and oral
opioids seems to be less effective with regard to pain
control.
Apart from good pain control the application of CEA
is advantageous in multiple regards: First the lung func-
tion and blood flow in the legs are improved. Then the
neuro-endocrine stress reaction and the myocardial oxy-
gen consumption are reduced and intestinal motility is
stimulated. This leads indirectly to a reduction in pul-
monary complications, thromboembolic episodes, as
well as other complications, shortens the hospital stay,
and decreases hospital costs [8]. The best pain control
seems to be if a local anaesthetic is combined with opi-
ates in the CEA and the combination of bupivacain, epi-
nephrine and fentanyl, has been recommended [1,9].
However, we have experienced frequent side effects with
pruritus and motor blockades as the most common
o n e s .O t h e rs t u d i e sr e p o r t ss i d ee f f e c t sa sp r u r i t u s
related to epidural opioids [3,4]. In a study of 1014
patients treated with CEA after major general surgical
procedure 82.6% had a good or excellent pain relief.
They had used a mixture of bupivacain and fentanyl and
just as in our study they encountered a high incidence
of pruritus. Other side effects related to fentanyl were
sedation and nausea, and to bupivacain were sensory
disturbances and motor blockades in the legs [2].
To avoid the side effects an ideal postoperative pain
regime would combine CEA using a drug with less
motor blockade effect than bupivacain with an opiate
administered in a way not leading to pruritus, i.e. not
epidurally. Ropivacaine has a milder side effect profile
Figure 1 The development of pruritus over time.
Figure 2 The development of motor blockade over time.
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control potential as bupivacain [10], which makes this
an interesting drug to investigate. Opiates could be
administered both orally and intravenously. On the one
hand intravenous opioid infusion would be easy to con-
trol but would require an additional infusion pump
which is awkward and resource consuming, and the
transition to oral analgesics on day four would still be a
potential problem. On the other hand if oral slow
release administration could be used already from the
start the problem of transition to oral medication would
be eliminated. Oral slow release oxycodone has been
shown to be an effective agent in postoperative pain
treatment in abdominal surgery, where it, in combina-
tion with infiltration of the wound with 25-40 ml 0.25%
bupivacaine was equipotent to CEA with bupivacain
[11]. The combination of CEA using ropivacain and oral
slow release oxycodone was chosen for the present
study. This would combine the positive effects of CEA
with improved pain control of a systemic opiate.
Another benefit would be that the patient could con-
tinue with the same oral analgesics after the CEA treat-
ment, which possibly could lower the risk of pain
breakthrough episodes. The present study was con-
ducted in order to compare this combination with the
traditional CEA with bupivacain, epinephrine and
fentanyl.
Being the most common side effect, leading regularly
to an early termination of CEA, pruritus was chosen as
our primary variable. We could demonstrate that pruri-
tus could be decreased to a great extent, but not be
eliminated when avoiding epidural morphine. Therefore
it is likely that postoperative pruritus is influenced by
further variables. For instance lying in bed for many
hours with wound dressings taped to the skin, in unfa-
miliar bed sheets washed with unfamiliar detergents
may still contribute to itching sensations even after the
pharmacological effect of epidural opiates have been
removed.
In our previous pilot study we saw motor blockades
quite frequently in CEA with bupivacain, epinephrine
and fentanyl (unpublished data). Because of its different
pharmacological properties we hypothesized that this
complication would have been less frequent when using
ropivacain. However motor blockade was reported by
almost half of the patients irrespective of treatment.
Thus, it seems like this complication is a rather una-
voidable part of CEA. Beyond that, the presented data
could not confirm a lesser effect on motor function of
ropivacain compared to other local anaesthetics, as
claimed by the manufacturer. Attempts to decrease this
effect by reducing the dose of ropivacain will most likely
also decrease the pain controlling effect.
The pain level was significantly higher in the new
treatment compared to the traditional one, which is still
an unaddressed problem of this oral opioid medication.
However, the pain levels in both groups were generally
low, with the mean value well below 40 VAS-units. The
Table 4 Motor blockade according to Bromage [5]
Motor blockade level Group B Group R
6 h Day1 Day2 Day3 Day4 6 h Day1 Day2 Day3 Day4
0 5 9 4 85 15 76 4 5 9 5 05 85 96 5
1 1 11 7 1 3 8 2 1 01 8 1 0 8 3
21 6 3 1 0 2 2 1 1 0
30 0 0 0 0 0 1 1 0 0
Figure 3 The development of pain over time.
Table 5 The total number of patients with pain
breakthrough episodes during the study period and
during day 4, i.e. the day of CEA removal, and the
number of patients receiving extra doses of opiates
during day 4
Group
B
Group
R
P
value
Patients with pain breakthrough episodes
total/n
40/66 43/69 0.49
Patients with pain breakthrough episodes
day 4/n
25/66 17/68 0.08
Patients receiving extra doses of opiates
day 4/n
54/66 55/68 0.89
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cal problem. The difference between the groups were in
the range of 10-14 VAS-units with is hardly of clinical
relevance. We have not found any reference values for
the minimally clinically important difference (MCID)
after surgery, but for low back pain patients it has been
estimated to be 18 of 100 VAS-units [12]. The small dif-
ference in pain control between the treatments is also
supported by the fact that the total number of pain
breakthrough episodes did not differ between the
groups. On the contrary, the group with bupivacain, epi-
nephrine and fentanyl had a tendency towards more
pain breakthrough episodes during the day of CEA
removal.
Conclusion
The pain control regime consisting of CEA with ropiva-
cain combined with oral slow release oxycodone
reduced the problem with pruritus when compared to
CEA with bupivacain, epinephrine and fentanyl, prob-
ably due to the elimination of epidural opiates. The
reduction in pruritus was associated with an increase in
pain score. Low grade motor blockade was equally fre-
quent during CEA treatment in both groups even
though more severe grades seldom occurred. The claim
by the manufacturer that ropivacain results in less effect
on motor function than other local anaesthetics could
not be confirmed.
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